Polyene phosphatidylcholine injection 930 mg QD + Magnesium Isoglycyrrhizinate injection 200 mg QD
ApprovedCompleted 0 views this week 0 watching⚡ Active
Interest: 43/100
43
Development Stage
✓
Pre-clinical✓
Phase 1✓
Phase 2✓
Phase 35
ApprovedIndication / Disease
Acute Drug Induced Liver Injury
Conditions
Acute Drug Induced Liver Injury
Trial Timeline
Apr 4, 2020 → Nov 2, 2020
NCT ID
NCT04595916About Polyene phosphatidylcholine injection 930 mg QD + Magnesium Isoglycyrrhizinate injection 200 mg QD
Polyene phosphatidylcholine injection 930 mg QD + Magnesium Isoglycyrrhizinate injection 200 mg QD is a approved stage product being developed by Haisco Pharmaceutical Group for Acute Drug Induced Liver Injury. The current trial status is completed. This product is registered under clinical trial identifier NCT04595916. Target conditions include Acute Drug Induced Liver Injury.
What happened to similar drugs?
20 of 20 similar drugs in Acute Drug Induced Liver Injury were approved
Approved (20) Terminated (4) Active (0)
✅Modification of Prasugrel based on a biological assay + prasugrel / clopidogrelDaiichi SankyoApproved
Hype Score Breakdown
Clinical
20
Activity
8
Company
15
Novelty
0
Community
0
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT04595916 | Approved | Completed |
Competing Products
20 competing products in Acute Drug Induced Liver Injury